Life Science Global Market Report 2026

Life science refers to the broad field of science that studies living organisms and biological processes, including disciplines such as biology, genetics, microbiology, biochemistry, and biotechnology. It focuses on understanding the structure, function, growth, and interaction of living systems at the molecular, cellular, and organism levels. It helps to advance knowledge that supports healthcare, agriculture, environmental sustainability, and the development of medical and biotechnological innovations.

The primary types of life science include biotechnology, pharmaceuticals, medical devices, life science tools, and digital health solutions. Biotechnology involves the application of living systems and organisms to develop or manufacture products for healthcare, research, and industrial purposes. These solutions cover therapeutic areas such as oncology, cardiology, neurology, immunology, rare diseases, and other therapeutic areas. The main applications include drug discovery and development, diagnostics, therapeutics, clinical trials, and research and development. These solutions are adopted by end users such as pharmaceutical companies, biotechnology companies, academic and research institutions, and hospitals and clinics.

Tariffs have impacted the life science market by increasing costs for imported laboratory instruments, reagents, analytical tools, and biotechnology products. The effect is most significant on life science tools and medical device segments, particularly in regions such as Europe and Asia-Pacific that rely on foreign manufacturing. Positive impacts include incentivizing local manufacturing and promoting adoption of domestic digital health solutions and research software, which can reduce dependency on imports and stimulate regional innovation.

The life science market size has grown rapidly in recent years. It will grow from $109.53 billion in 2025 to $123.41 billion in 2026 at a compound annual growth rate (CAGR) of 12.7%. The growth in the historic period can be attributed to growth in pharmaceutical r&d investments, expansion of biotechnology companies, adoption of laboratory automation, increasing demand for diagnostics, rising prevalence of chronic and rare diseases.

The life science market size is expected to see rapid growth in the next few years. It will grow to $200.59 billion in 2030 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to advancements in precision medicine, growth in digital health solutions, integration of ai and big data analytics in research, increasing collaborations between academic and commercial research institutions, expansion of global clinical trials. Major trends in the forecast period include advanced drug discovery platforms, integrated clinical trial management, high-throughput laboratory automation, regulatory compliance and consulting services, bioinformatics and data analytics.

The increasing prevalence of chronic diseases is expected to drive the growth of the life science market going forward. Chronic diseases refer to long-term conditions that typically progress slowly and require continuous management rather than short-term care. The prevalence of chronic diseases is rising due to unhealthy lifestyle patterns such as poor nutrition, physical inactivity, and increasing obesity levels. The life science sector addresses chronic diseases by enabling the development of new therapies, diagnostics, and biologics that enhance long-term disease management and patient outcomes. For instance, in April 2025, according to the Centers for Disease Control and Prevention, a US-based government agency, in 2023, 76.4% of US adults, representing 194 million people, reported one or more chronic conditions, including 59.5%, 78.4%, and 93.0% among young, midlife, and older adults, respectively. Therefore, the increasing prevalence of chronic diseases is driving the growth of the life science market.

Leading companies in the life science market are focusing on developing innovative products, such as patented peptide-based functional ingredients, to provide scientifically validated support for glucose regulation and metabolic health. Peptide-based functional ingredients are bioactive, short-chain amino acid compounds designed to interact with specific metabolic pathways to deliver targeted health benefits. For example, in December 2025, Greenyn Biotechnology Co. Ltd., a Taiwan-based provider of proprietary biotechnology-driven functional ingredients and health supplement solutions, launched Insumate mcIRBP-19 Bitter Melon Peptide, a bioactive peptide designed to support metabolic health in dietary supplement applications. The product features a uniquely identified bitter melon-derived peptide that mimics insulin receptor binding activity, supporting blood glucose control. It is produced using a low-temperature supercritical extraction process to preserve peptide bioactivity and consistency. Insumate mcIRBP-19 is backed by clinical validation and international certifications, positioning it as a next-generation, evidence-based nutraceutical ingredient targeting the rapidly growing metabolic health and diabetes-support segment.

In October 2025, MJH Life Sciences, a US-based healthcare information and analytics company, acquired BPD Healthcare for an undisclosed amount. With this acquisition, MJH Life Sciences broadened its medical education, healthcare communications, and marketing capabilities to better serve pharmaceutical, life sciences, and healthcare professional audiences. BPD Healthcare is a US-based company focused on healthcare communications and strategic medical marketing services.

Major companies operating in the life science market are Johnson & Johnson, Roche Holding AG, Pfizer Inc., AbbVie Inc., AstraZeneca plc, Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Sanofi S.A., Abbott Laboratories, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Novo Nordisk A/S, Amgen Inc., Eli Lily and Company, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Merck KGaA, Boehringer Ingelheim International GmbH, Vertex Pharmaceuticals Incorporated, Astellas Pharma Inc., Biogen Inc., bioMerieux SA, Sartorius AG

North America was the largest region in the life science market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the life science market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the life science market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The life science market consists of revenues earned by entities by providing services such as research and development services, clinical trial management, laboratory testing and analysis, regulatory and compliance consulting, and bioinformatics support. The market value includes the value of related goods sold by the service provider or included within the service offering. The life science market also includes sales of laboratory instruments, analytical equipment, reagents and consumables, biotechnology products, diagnostic kits, and research tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The life science market research report is one of a series of new reports from The Business Research Company that provides life science market statistics, including life science industry global market size, regional shares, competitors with a life science market share, detailed life science market segments, market trends and opportunities, and any further data you may need to thrive in the life science industry. This life science market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Life Science Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses life science market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for life science ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The life science market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Biotechnology; Pharmaceuticals; Medical Devices; Life Science Tools; Digital Health Solutions
• 2) By Therapeutic Areas: Oncology; Cardiology; Neurology; Immunology; Rare Diseases; Other Therapeutic Areas
• 3) By Applications: Drug Discovery And Development; Diagnostics; Therapeutics; Clinical Trials; Research And Development
• 4) By End-User: Pharmaceutical Companies; Biotechnology Companies; Academic And Research Institutions; Hospitals And Clinics
• Subsegments:
• 1) By Biotechnology: Genetic Engineering; Cell Based Technologies; Microbial Biotechnology; Industrial Biotechnology; Agricultural Biotechnology
• 2) By Pharmaceuticals: Prescription Drugs; Over The Counter Drugs; Generic Drugs; Branded Drugs; Specialty Drugs
• 3) By Medical Devices: Diagnostic Devices; Therapeutic Devices; Surgical Instruments; Monitoring Devices; Implantable Devices
• 4) By Life Science Tools: Laboratory Instruments; Reagents And Consumables; Analytical Tools; Sample Preparation Tools; Research Software Solutions
• 5) By Digital Health Solutions: Health Information Systems; Remote Patient Monitoring; Mobile Health Applications; Clinical Decision Support Systems; Healthcare Data Analytics
• Companies Mentioned: Johnson & Johnson; Roche Holding AG; Pfizer Inc.; AbbVie Inc.; AstraZeneca plc; Bayer AG; Novartis AG; Bristol-Myers Squibb Company; Sanofi S.A.; Abbott Laboratories; Thermo Fisher Scientific Inc.; GlaxoSmithKline plc; Novo Nordisk A/S; Amgen Inc.; Eli Lily and Company; Takeda Pharmaceutical Company Limited; Gilead Sciences Inc.; Merck KGaA; Boehringer Ingelheim International GmbH; Vertex Pharmaceuticals Incorporated; Astellas Pharma Inc.; Biogen Inc.; bioMerieux SA; Sartorius AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.